280 related articles for article (PubMed ID: 36051422)
1. Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
Singh AK; Singh R
World J Diabetes; 2022 Jul; 13(7):471-481. PubMed ID: 36051422
[TBL] [Abstract][Full Text] [Related]
2. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
4. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
Mima A
Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
[TBL] [Abstract][Full Text] [Related]
5. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
[TBL] [Abstract][Full Text] [Related]
8. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
9. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
Rossing P; Filippatos G; Agarwal R; Anker SD; Pitt B; Ruilope LM; Chan JCN; Kooy A; McCafferty K; Schernthaner G; Wanner C; Joseph A; Scheerer MF; Scott C; Bakris GL;
Kidney Int Rep; 2022 Jan; 7(1):36-45. PubMed ID: 35005312
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease.
Shah M; Awad AS; Abdel-Rahman EM
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834929
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
Ortiz A; Ferro CJ; Balafa O; Burnier M; Ekart R; Halimi JM; Kreutz R; Mark PB; Persu A; Rossignol P; Ruilope LM; Schmieder RE; Valdivielso JM; Del Vecchio L; Zoccali C; Mallamaci F; Sarafidis P;
Nephrol Dial Transplant; 2023 Jan; 38(1):10-25. PubMed ID: 33944938
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
Yao L; Liang X; Wang P
Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
[TBL] [Abstract][Full Text] [Related]
13. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
Haller H
Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
Barrera-Chimal J; Lima-Posada I; Bakris GL; Jaisser F
Nat Rev Nephrol; 2022 Jan; 18(1):56-70. PubMed ID: 34675379
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.
Palanisamy S; Funes Hernandez M; Chang TI; Mahaffey KW
Cardiol Ther; 2022 Sep; 11(3):337-354. PubMed ID: 35737275
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.
Fernandez-Fernandez B; Sarafidis P; Kanbay M; Navarro-González JF; Soler MJ; Górriz JL; Ortiz A
Clin Kidney J; 2020 Oct; 13(5):728-733. PubMed ID: 33123352
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
Cohen S; Sternlicht H; Bakris GL
Curr Diab Rep; 2022 May; 22(5):213-218. PubMed ID: 35441935
[TBL] [Abstract][Full Text] [Related]
18. An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria.
Bramlage P; Lanzinger S; Mühldorfer S; Milek K; Gillessen A; Veith R; Ohde T; Danne T; Holl RW; Seufert J
Cardiovasc Diabetol; 2023 May; 22(1):108. PubMed ID: 37158855
[TBL] [Abstract][Full Text] [Related]
19. Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus.
Rastogi A; Weir MR
J Diabetes Complications; 2023 Aug; 37(8):108515. PubMed ID: 37356235
[TBL] [Abstract][Full Text] [Related]
20. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
Al Dhaybi O; Bakris GL
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():69-76. PubMed ID: 32267074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
